Centre National De La Recherche Scientifique

Commissariat a L'energie Atomique

Institut National De La Sante Et De La Recherche Medicale

Université Joseph Fourier

Commissariat a L'energie Atomique Et Aux Energies Alternatives

Université Grenoble Alpes

Université Joseph Fourier - Grenoble 1

Université De Caen Normandie

Centre Hospitalier Universitaire De Grenoble

Centre Regional Francois Baclesse

Centre Hospitalier Universitaire Grenoble

Jean-Paul Issartel

Didier Molko

Sylvie Sauvaigo

Jean-François Mouret

Florence Marciacq

François Berger

Laurent Pelletier

Sandra Boccard

David Ratel

Alim-Louis Benabid

Ali Bouamrani

Laurent Poulain

Jean-Guy Passagia

Audrey Guttin

Mégane Vernon

Bernard Lambert

Matthieu Meryet-figuiere

Christophe Denoyelle

Nicolas Vigneron

Renaud Montessuy

Emmanuel Gay

Elodie Lages

Michèle El Atifi-Borel

Berger François

The present disclosure relates to the identification of a biomarker, consisting in a circulating miRNA, suitable for use in the diagnosis and prognosis of high-grade serous ovarian carcinoma (HGSOC), and to diagnostic kits for use in such diagnosis.

Predictive and prognostic use of a miRNA for high grade serous ovarian carcinoma therapeutic care

The present disclosure relates to a surgical instrument for sampling molecules in an organ which can be accessed directly or via a surgical portal, including:

Surgical instrument for molecular sampling

The present invention relates to a sampling instrument adapted for taking a sample in situ and in vivo or taking a sample ex vivo of a target tissue or body structure, in a maximum quantity of less than 10g, the instrument comprising an elongated active member () with a distal operative end () having at least one retaining surface () arranged for contacting directly the target tissue or body structure, capturing and retaining molecules of the target tissue or body structure thereto.

Method for determining the molecular composition of a target tissue or another body structure, and its diagnostic applications

The invention relates to the identification of genes involved in resistance of cancer cells to therapy, to short nucleic acid molecules which inhibit the expression of these genes by RNA interference and to their use as adjuvant in cancer therapy, to sensitize cancer cells to conventional anticancer agents; the short nucleic acid molecules are double-stranded short interfering nucleic acid molecules including a sense and an antisense region, wherein the sense region includes a nucleotide sequence that is selected from the group consisting of: the sequences SEQ ID NO: 15, 11, 13, 14, 30, 31, 38, 46, 64 and 70 and the sequences having at least 70% identity, preferably at least 80% identity, more preferably at least 90% identity with the sequences, and the antisense region includes a nucleotide sequence that is complementary to the sense region.

Sensizitation of cancer cells to therapy using sina targeting genes from the 1P and 19Q chromosomal regions

Sensizitation of cancer cells to therapy using siNA targeting genes from the 1p and 19q chromosomal regions

The invention relates to the use of morpholino-nucleosides of formula: in which Rrepresents a nucleic base and Rrepresents a group corresponding to one of the following formulae:&#x2014;(CH)&#x2014;NH&#x2014;(CH)&#x2014;SH&#x2014;(CH)&#x2014;COOH &#x2014;(CH)&#x2014;OH&#x2014;(CH)&#x2014;NH&#x2014;R&#x2014;(CH)&#x2014;SR&#x2014;(CH)&#x2014;CO&#x2014;R&#x2014;(CH)&#x2014;ORin which n is an interger ranging from 1 to 12 and Ris a group derived from a label, from a protein, from an enzyme, from a fatty acid or from a peptide, as chain terminators in a process of DNA or RNA sequencing by the Sanger method, or for the labelling of DNA or RNA fragments.

Process for manufacturing morpholino-nucleotides, and use thereof for the analysis of and labelling of nucleic acid sequences

The invention relates to the use of morpholino-nucleosides of formula: in which Rrepresents a nucleic base and Rrepresents a group corresponding to one of the following formulae:&#x2014;(CH)&#x2014;NH&#x2014;(CH)&#x2014;SH&#x2014;(CH)&#x2014;COOH &#x2014;(CH)&#x2014;OH&#x2014;(CH)&#x2014;NH&#x2014;R&#x2014;(CH)&#x2014;SR&#x2014;(CH)&#x2014;CO&#x2014;R&#x2014;(CH)&#x2014;OR

The invention relates to the use of morpholino-nucleosides of formula:in which Rrepresents a nucleic base and Rrepresents a group corresponding to one of the following formulae:

Growing community of inventors

Saint Egreve, France

Jean-Paul Issartel